<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254241</url>
  </required_header>
  <id_info>
    <org_study_id>BU-5077-0011</org_study_id>
    <nct_id>NCT00254241</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Seroquel in First Episode Schizophrenia</brief_title>
  <official_title>Safety and Efficacy of Seroquel in First Episode Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode
      schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients developing clinically significant EPS at any point between baseline (day 1) and final assessment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI severity of illness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI global improvement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS total score and subscales)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale (AIMS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of anti cholinergic medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prolactin levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients discontinuing treatment due to reasons of lack of efficacy or adverse effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing relapse.</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seroquel and Risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35 years Meet ICD-10 criteria for schizophrenia No abnormaility on clinical
             examination No previous episode of psychosis No previous antipsychotics of any kind in
             last 3 months

        Exclusion Criteria:

          -  Have received a course of antipsychotics drug treatment prior to entry which may
             introduce risk factors or interfere with study procedures Have received
             anticholinergics within 10 days of baseline aseessment Have received mood stabilizers
             or anti depressants within 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Seroquel Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZenenca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2005</study_first_posted>
  <last_update_submitted>June 9, 2009</last_update_submitted>
  <last_update_submitted_qc>June 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

